Literature DB >> 20166847

Minimal mesangial lupus nephritis: a systematic review.

C C Mok1, T T Cheung, W H Lo.   

Abstract

OBJECTIVES: To summarize the clinical presentation, histological features, treatment, and outcome of minimal change nephropathy (MCN) in patients with systemic lupus erythematosus (SLE).
METHODS: We performed a systematic review of cases of MCN in SLE patients reported in the English literature from January 1985 to May 2009 by a Medline search.
RESULTS: The estimated prevalence of MCN in biopsy-proven lupus nephritis is 2.3% in childhood and 1.1% in adults. There are 13 individual cases (12 women, one man) of SLE-related MCN reported in the literature. The mean age of nephritis onset was 32.7 years. In six (46%) patients, MCN was the initial manifestation of SLE. All patients presented with nephrotic syndrome and two (15%) had active urinary sediments. Renal function was impaired in eight (62%) patients and six (46%) patients had active lupus serology. All patients responded promptly to high-dose glucocorticoids but four (31%) had relapse of proteinuria during their course of SLE. None of the patients developed thromboembolic or infective complications.
CONCLUSIONS: MCN is an uncommon histological class of lupus nephritis. Typically, patients present with heavy proteinuria, and transient renal dysfunction is common. The prognosis of MCN in SLE appears to be good because of its rapid response to glucocorticoids. Relapses of proteinuria may be reduced by the use of maintenance immunosuppression. Alkylating agents, calcineurin inhibitors, mycophenolate mofetil, and rituximab can be considered in glucocorticoid-dependent or refractory cases of SLE-related MCN.

Entities:  

Mesh:

Year:  2010        PMID: 20166847     DOI: 10.3109/03009740903456300

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  8 in total

Review 1.  Lupus podocytopathy: a distinct entity of lupus nephritis.

Authors:  Duqun Chen; Weixin Hu
Journal:  J Nephrol       Date:  2017-12-22       Impact factor: 3.902

2.  Clinical-Morphological Features and Outcomes of Lupus Podocytopathy.

Authors:  Weixin Hu; Yinghua Chen; Shaofan Wang; Hao Chen; Zhengzhao Liu; Caihong Zeng; Haitao Zhang; Zhihong Liu
Journal:  Clin J Am Soc Nephrol       Date:  2016-03-16       Impact factor: 8.237

Review 3.  Pure lupus podocytopathy first presenting as thrombotic thrombocytopenic purpura-like syndrome.

Authors:  Guillermo Delgado-García; Carlos Cámara-Lemarroy; Adrián Infante-Valenzuela; Perla Colunga-Pedraza; Gabriela Alarcón-Galván; Arian Armenta-González; Héctor Jorge Villarreal-Velázquez
Journal:  Clin Rheumatol       Date:  2015-09-18       Impact factor: 2.980

4.  The kidney biopsy in lupus nephritis: is it still relevant?

Authors:  Brad H Rovin; Samir V Parikh; Anthony Alvarado
Journal:  Rheum Dis Clin North Am       Date:  2014-06-07       Impact factor: 2.670

Review 5.  Lupus nephritis.

Authors:  Hans-Joachim Anders; Ramesh Saxena; Ming-Hui Zhao; Ioannis Parodis; Jane E Salmon; Chandra Mohan
Journal:  Nat Rev Dis Primers       Date:  2020-01-23       Impact factor: 52.329

6.  Understanding lupus nephritis: diagnosis, management, and treatment options.

Authors:  Chi Chiu Mok
Journal:  Int J Womens Health       Date:  2012-05-22

Review 7.  Do we still need renal biopsy in lupus nephritis?

Authors:  Ewa Haładyj; Ricard Cervera
Journal:  Reumatologia       Date:  2016-06-03

8.  Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

Authors:  George K Bertsias; Maria Tektonidou; Zahir Amoura; Martin Aringer; Ingeborg Bajema; Jo H M Berden; John Boletis; Ricard Cervera; Thomas Dörner; Andrea Doria; Franco Ferrario; Jürgen Floege; Frederic A Houssiau; John P A Ioannidis; David A Isenberg; Cees G M Kallenberg; Liz Lightstone; Stephen D Marks; Alberto Martini; Gabriela Moroni; Irmgard Neumann; Manuel Praga; Matthias Schneider; Argyre Starra; Vladimir Tesar; Carlos Vasconcelos; Ronald F van Vollenhoven; Helena Zakharova; Marion Haubitz; Caroline Gordon; David Jayne; Dimitrios T Boumpas
Journal:  Ann Rheum Dis       Date:  2012-07-31       Impact factor: 19.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.